MAPK3 and cardiac hypertrophy: Under HFpEF, the protective effects of lovastatin on diastolic functions (Fig. 7A–C and Supplementary Table 4), cardiac hypertrophy and fibrosis (Figs. 7A, D, E), and exercise capacity (Fig. 7F) were observed in tamoxifen-injected CDH5-Cre-ERT2 mice, but not in tamoxifen-injected AP-2αflox/flox/CDH5-Cre-ERT2 mice.